{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T21:26:14Z","timestamp":1791494774335,"version":"4.3.4"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000765","name":"University College London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000765","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008667","name":"National Cancer Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008667","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012317","name":"UCLH Biomedical Research Centre","doi-asserted-by":"publisher","award":["C21279\/A13359"],"award-info":[{"award-number":["C21279\/A13359"]}],"id":[{"id":"10.13039\/501100012317","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.ygyno.2020.09.048","type":"journal-article","created":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T13:31:19Z","timestamp":1602855079000},"page":"692-698","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer"],"prefix":"10.1016","volume":"159","author":[{"given":"M.R.","family":"Hall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.-M.","family":"Dehbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Lord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Clamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.","family":"Ledermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Nicum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Lilleywhite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Bowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Michael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Feeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Glasspool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Hackshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Rustin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2020.09.048_bb0005","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2020.09.048_bb0010","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum resistant recurrent ovarian cancer:The AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.09.048_bb0015","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S1470-2045(15)70115-4","article-title":"Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial","volume":"16","author":"Pignata","year":"2015","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.ygyno.2020.09.048_bb0020","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s12094-008-0254-7","article-title":"Combined oral cyclophosphamide and bevacizumab in heavily pretreated ovarian cancer","volume":"10","author":"Jurado","year":"2008","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.ygyno.2020.09.048_bb0025","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1200\/JCO.2007.12.1939","article-title":"Phase II clinical trial of bevacizumab and low-dose metronomic cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret hospital phase II consortia","volume":"26","author":"Garcia","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.09.048_bb0030","doi-asserted-by":"crossref","DOI":"10.1159\/000320602","article-title":"Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer","volume":"79","author":"Sanchez-Munoz","year":"2010","journal-title":"Oncology"},{"issue":"23","key":"10.1016\/j.ygyno.2020.09.048_bb0035","first-page":"6938","article-title":"Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective anti-angiogenic window for various chemotherapeutic drugs","volume":"62","author":"Bocci","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2020.09.048_bb0040","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/annonc\/mdf013","article-title":"Low dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumour activity and correlation with vascular endothelial growth factor levels","volume":"13","author":"Colleoni","year":"2002","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2020.09.048_bb0045","doi-asserted-by":"crossref","first-page":"5601","DOI":"10.1200\/JCO.2009.23.2777","article-title":"Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer","volume":"27","author":"Matulonis","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2020.09.048_bb0050","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ygyno.2010.05.033","article-title":"(2010). A phase II open label study evaluating pazopanib with recurrent ovarian cancer","volume":"119","author":"Friedlander","year":"2010","journal-title":"Gynecol. Oncol."},{"issue":"28","key":"10.1016\/j.ygyno.2020.09.048_bb0055","doi-asserted-by":"crossref","first-page":"3798","DOI":"10.1200\/JCO.2010.33.5208","article-title":"Randomized phase II placebo-controlled trial of maintenance therapy using the Oral triple Angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian Cancer","volume":"29","author":"Ledermann","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.ygyno.2020.09.048_bb0060","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1471-0528.1979.tb10799.x","article-title":"The treatment of advanced cystadenocarcinoma of the ovary with gestronol and continuous oral cyclophosphamide","volume":"86","author":"Guthrie","year":"1997","journal-title":"Br. J. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2020.09.048_bb0065","first-page":"467","article-title":"A retrospective review of low dose oral cyclophosphamide alone and in combination with tamoxifen and prophylactic warfarin in heavily pretreated ovarian cancer","volume":"1","author":"Hall","year":"2010","journal-title":"IJGC"},{"key":"10.1016\/j.ygyno.2020.09.048_bb0070","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s10147-010-0094-1","article-title":"Feasibility study of oral cyclophosphamide salvage therapyfor the treatment of heavily pretreated patients with recurrentepithelial ovarian cancer","volume":"15","author":"Watanabe","year":"2010","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.09.048_bb0075","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.tjog.2017.04.006","article-title":"Continuous oral cyclophosphamide as salvage or maintenance therapy in ovarian, primary peritoneal, and fallopian tube cancers: A retrospective, single institute study","volume":"56","author":"Wong","year":"2017","journal-title":"2017 Taiwan. J. Obstet. Gynecol."},{"issue":"18","key":"10.1016\/j.ygyno.2020.09.048_bb0080","doi-asserted-by":"crossref","first-page":"6678","DOI":"10.1158\/1078-0432.CCR-05-0621","article-title":"Metronomic low-dose chemotherapy boosts CD95-dependent Antiangiogenic effect of the Thrombospondin peptide ABT-510: a complementation antiangiogenic strategy. 2005","volume":"11","author":"Yap","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2020.09.048_bb0085","first-page":"40","article-title":"Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide","volume":"13","author":"Emmenegger","year":"2011","journal-title":"2011 Neoplasia"},{"key":"10.1016\/j.ygyno.2020.09.048_bb0090","doi-asserted-by":"crossref","unstructured":"International Breast Cancer Study Group (IBCSG) Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node\u2013negative breast cancer: a randomized trial JNCI: J. Nat. Cancer Institute, 95, (24), 17 December 2003, Pages 1833\u20131846.","DOI":"10.1093\/jnci\/djg119"},{"key":"10.1016\/j.ygyno.2020.09.048_bb0095","article-title":"Oral cyclophosphamide in recurrent ovarian cancer","author":"Handolias","year":"2013","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.ygyno.2020.09.048_bb0100","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11136-017-1729-8","article-title":"Measuring what matters MOST: validation of the measure of ovarian symptoms and treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer","volume":"27","author":"King","year":"2018","journal-title":"Qual. Life Res."},{"issue":"1","key":"10.1016\/j.ygyno.2020.09.048_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"NEJM"},{"issue":"32","key":"10.1016\/j.ygyno.2020.09.048_bb0110","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.1200\/JCO.2015.63.1408","article-title":"Bevacizumab combined with weekly paclitaxel, lipsomoal doxorubicin or topotecan in platinum resistant recurrent ovarian cancer: analysis by chemotherapy cohort of the randomized phase III AURELIA trial","volume":"33","author":"Poveda","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.09.048_bb0115","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1186\/1471-2407-14-947","article-title":"Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study","volume":"14","author":"Ferrandina","year":"2014","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2020.09.048_bb0120","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3802\/jgo.2013.24.3.258","article-title":"The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer","volume":"24","author":"Barber","year":"2013","journal-title":"J. Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.09.048_bb0125","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ygyno.2017.05.013","article-title":"Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - results of the PACOVAR-trial","volume":"146","author":"Dinkic","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.09.048_bb0130","doi-asserted-by":"crossref","unstructured":"Scurr M, Pembroke T, Bloom A, et al. Effect of modified vaccinia ankara\u20135T4 and low-dose cyclophosphamide on antitumor immunity in metastatic colorectal cancer Random. Clin. Trial Clin. Cancer Res. 2017 Nov 15;23(22):6771\u20136780. doi: https:\/\/doi.org\/10.1158\/1078-0432","DOI":"10.1001\/jamaoncol.2017.2579"},{"key":"10.1016\/j.ygyno.2020.09.048_bb0135","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukarama","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2020.09.048_bb0140","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1093\/gastro\/goz060","article-title":"Antitumor immunity of low-dose cyclophosphamide: changes in T cells and cytokines TGF-beta and IL-10 in mice with colon-cancer liver metastasis","volume":"8","author":"Huang","year":"2020","journal-title":"Gastroenterol. Rep."},{"key":"10.1016\/j.ygyno.2020.09.048_bb0145","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ctrv.2015.11.005","article-title":"Low dose cyclophosphamide: mechanisms of T cell modulation","volume":"42","author":"Madondo","year":"2016","journal-title":"Cancer Treat. Rev."},{"issue":"7","key":"10.1016\/j.ygyno.2020.09.048_bb0150","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1158\/1078-0432.CCR-14-2565","article-title":"Randomised trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA mutant ovarian cancer","volume":"21","author":"Kummar","year":"2015","journal-title":"Clin. Cancer Res."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820339585?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820339585?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:56:29Z","timestamp":1758772589000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825820339585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S0090825820339585"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.09.048","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.09.048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}